At DDW Medical Conference, Dynavax (DVAX) Presents Additional Phase 3 Data for HEPLISAVTM Hepatitis B Vaccine
Up)
Dynavax Technologies Corporation (Nasdaq: DVAX) presented additional Phase 3 clinical data for HEPLISAVTM hepatitis B vaccine in a poster session at the Digestive Disease Week (DDW) medical conference in Chicago. In addition to meeting its primary endpoint in this Phase 3 trial as previously reported, HEPLISAV provided more rapid and increased seroprotection against hepatitis B viral infection and with fewer doses than the licensed vaccine. The data show the differences to be particularly significant in the subset of subjects over 40 years of age who are usually less likely to respond to immunization.
You May Also Be Interested In
- Auxilium (AUXL) Files Suit Against Watson (WPI) Over Testim 1% Gel
- IsoRay (ISR) Says GliaSite System Received CE Mark; to Go On Sale in 31 European Markets
- Auxilium Pharma (AUXL), Glaxo (GSK) Enter Testim 1% Co-Promotion Agreement
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
